Table 3.

Main results obtained comparing Infliximab (IFX) and Vedolizumab (VDZ) in naïve patients with Ulcerative Colitis.

	IFX (n = 50)	VDZ (n = 32)	p value
Duration of clinical FU, mean (weeks)	37	45	0.154
Subjects in CR at the end of FU, n (%)	16 (32%)	24 (75%)	0.0003
Drug persistency at the end of FU, n (%)	26 (52%)	25 (78%)	0.033
Subjects who achieved CR at the end of FU	23	21	0.130
Time to obtain CR (weeks, median)	8.7	13	0.885
Response at the end of induction, n (%)	27 (54%)	26 (81%)	0.014
Steroid-free remission at the end of FU compared to patients who used steroids at baseline, n (%)	13/21 (62%)	17/18 (94%)	0.036
Need for optimization, n (%)	29 (57%)	9 (28%)	0.009
Primary non-response	15 (30%)	3 (9%)	0.027
Secondary loss of response (immunogenic or not)	3 (6%)	3 (9%)	0.327
Adverse events, n (%)	7 (14%)	1 (3%)	0.139
CRP normalization at the end of induction, n (%)	15/38 (39%)	10/19 (53%)	0.347

p value was obtained by chi-square, exact Fisher, odds ratio, log-rank test, and t Student’s test.

FU follow-up, CRP C-reactive protein.

Significant values are in bold.